Search published articles


Showing 3 results for Propranolol
Efficacy of Propranolol and Amiodarone on Prevention of Atrial Fibrillation after CABG
Forouzan-Nia S.k, Abdollahi M.h , Motafakker M , Dehghan Hr , Rajabiun H ,
Volume 64, Issue 7 (8-2006)
Abstract
Background: Atrial fibrillation is the most common arrhythmia following CABG. This complication can cause palpitation, significant hemodynamic instability and thromboembolic events. This prospective randomized study evaluate prophylactic effects of propranolol low dose amiodarone and high dose amiodarone in patients candidate for CABG.
Methods: Three hundred consecutive patients undergoing elective CABG were randomly categorized into three groups (each group contains 100 patients). Patients in group1 (control group) received 10mg/TDS propranolol per oral (P.o), preoperatively. Patients in group 2 received 10mg propranolol TDS, P.o plus 350mg/24h amiodarone. Patients in group 3 received 10mg propranolol TDS P.o plus 1000mg/24h amiodarone 24 hours before operation.
Results: Atrial fibrillation occurred in 12 patients (12%) in group 1, four patients (4%) in group 2 and 10 patients (10%) (P=0.035) in group 3. AF occurred in 10.36% of men and 3.84% of women. There was no AF in off- pump groups and 9.73% in on-pump groups
Conclusion: This study suggested the combination of propranolol plus low dose amiodarone for post CABG atrial fibrillation prophylaxy.
The evaluation of late outcome of balloon pulmonary valvuloplasty in children
Nakhostin Davari P, Mortazaeian Langrodi H, Ghaemi Hr,
Volume 69, Issue 8 (11-2011)
Abstract

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 Background: Isolated pulmonary valve stenosis represents 8-10% of congenital cardiac anomalies. This study was performed to evaluate the late outcomes of Balloon Pulmonary Valvuloplasty (BPV) in children with residual infundibular stenosis.
Methods : Seventy-eight patients underwent BPV in Rajaee Heart Center in Tehran Iran, from 2008-2010. The patients were divided into two groups: with and without infundibular stenosis. The group with infundibular stenosis was subdivided into two groups: with and without propranolol administration. Gradient measurement follow-ups by Doppler echocardiography were done on the first day and 1, 3, 6 and 12 months afterwards.
Results: Thirty five (44.9%) patients were male and 43 (55.1%) were female. The mean age of participants was 4.29±3.5 years and the mean weight 16.18±8.8 kg 33 patients (43%) did not show residual infundibular stenosis but 45 (57%) did so in the evaluations. There were no significant differences between the two groups regarding age, weight, sex, kind of balloon valvuplasty, balloon to body surface area ratio and pulmonary regurgitation (PR). Propranolol was administered to 27 (60%) patients with residual stenosis for six months but 18 (40%) did not receive the medication. In both groups, the gradient significantly decreased immediately after BPV (P<0.0001). In the propranolol group a constant decrease in residual gradient was seen. There was a significant relationship between balloon to body surface area ratio (387±94mm2/m2) with moderate to severe PR (P<0.015).
Conclusion: BPV is a safe and effective procedure to treat PS. Residual infundibular gradient after BPV decreases over time and propranolol helps decrease the gradient.


A comparative study of the efficacy of coenzyme Q10 and propranolol in prophylaxis of migraine headaches: a double-blinded clinical trial
Hadi Gharebaghian, Azar Ghasemi , Elaheh Hoseinpour,
Volume 80, Issue 9 (12-2022)
Abstract

Background: Migraine is a recurrent disease which its definitive mechanism is still unknown. Thus mitochondrial dysfunction and neurovascular damage are two hypothetical underlying mechanisms for migraine headaches. The effectiveness of some possibly effective compounds such a CoQ10 has been studied. In this study, we evaluated the efficacy of coenzyme Q10 in migraine headache prophylaxis.
Methods: This study was performed as a double-blinded randomized clinical trial on 112 patients with a diagnosis of migraine who were referred to the Neurology Clinic of Imam Reza Hospital in Kermanshah from March to September 2018. Then the patients were randomly divided into two equal groups (control and intervention). Both groups received propranolol 20 mg twice daily (totally 40 mg/d). The intervention group was treated by CoQ10 60 mg once daily, additionally. Finally, the quantitative and qualitative characteristics of migraine headaches such as nausea and vomiting, photophobia, phonophobia, severity, frequency and duration of attacks were evaluated by Student's t-test, Mann-Whitney U test and Wilcoxon tests.
Results: At the end, it was concluded that CoQ10 supplement of 60 mg daily with propranolol 40 mg daily in patients with migraine headaches improves symptoms more than receiving propranolol 40 mg alone. The results also showed that in the intervention group, nausea and vomiting, photophobia and the severity of headache in patients significantly improved compared to the control group (P values of 0.001, 0.114 and 0.001, respectively). However, the symptoms of phonophobia, frequency and duration of headache attack in the intervention group were not significantly different from the control group (P values were 0.062, 0.853 and 0.106, respectively).
Conclusion: In conclusion considering the main goal of this study, consumption of CoQ10 60 mg daily with propranolol 40 mg daily significantly improves symptoms such as nausea and vomiting, photophobia and severe headache compared to propranolol 40 mg daily. In conclusion, CoQ10 is a suitable choice in patients who do not respond adequately to the standard drug regimen.


Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb